Boehringer Ingelheim and Ashoka’s Changemakers Launch "Making More Health" Competition
July 6, 2011 - This worldwide competition invites the most innovative models and solutions that are transforming the field of health today.
http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/06_july_2011_ashokaschangemakers.html

Boehringer Ingelheim and AVEO Pharmaceuticals announce manufacturing agreement for ficlatuzumab
December 1st, 2011 – Boehringer Ingelheim will produce ficlatuzumab for clinical trials at its biopharmaceutical site in Fremont, USA.
http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/01_december_2011aveo.html

Boehringer Ingelheim and Gilead sign license agreement for novel HIV non-catalytic integrase inhibitors
October 6, 2011 – This includes the lead compound BI 224436, which has been evaluated in a Phase 1a dose-escalation study to assess bioavailability and pharmacokinetics in healthy volunteers.
http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/06_october_2011_gilead.html

Boehringer Ingelheim and Zealand Pharma enter into a licence and collaboration agreement
16 June 2011 - Boehringer Ingelheim and Zealand Pharma enter into a licence and collaboration agreement to advance novel compounds to treat Type-2 diabetes and obesity.
http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/16_june_2011_collaboration_partners.html

Boehringer Ingelheim Broadens its Breast Cancer Trial Programme for Afatinib*
29 August, 2011 – Two phase II studies investigating afatinib* in erbB2 (HER2)-overexpressing, metastatic or inflammatory breast cancer are open for recruitment.
http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/29_august_2011_oncology.html

Boehringer Ingelheim completes patient entry for Phase III trial
December 9th, 2011 – The extensive study programme is underway at more than 350 sites in 15 countries and together encompasses nearly 2,000 treatment-experienced as well as treatment-naïve patients.
http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/09_december_2011hepc.html

Boehringer Ingelheim extends "one stop shop" service with new fill and finish capabilities
June 20th , 2011 - The new line is available as of today for contract filling of liquid and lyo vials from 0,5 ml- 100 ml.
http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/20_june_2011_onestopshop.html

Boehringer Ingelheim licenses ProBioGen's novel GlymaxX® technology
10 August 2011 –Boehringer Ingelheim and ProBioGen AG announced today that they have signed a non-exclusive Licensing Agreement regarding ProBioGen’s GlymaxX® technology.
http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/10_august_2011_probiogen.html

Boehringer Ingelheim/Pfizer position regarding the recent publication by Singh et. al., in British Medical Journal, June 15, 2011
On 15 June 2011, results by Singh et al from a meta-analysis of randomized controlled trials was published in British Medical Journal.
http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2011/15_june_2011_copd.html

Brain tumour promoting pathway discovery could lead to new treatment
A cellular pathway that cancer stem cells use to promote tumour growth in malignant glioma, an aggressive brain tumour, has been identified by Cleveland Clinic researchers.
http://www.andhranews.net/Technology/2011/Brain-tumour-promoting-pathway-discovery-could-4571.htm

Anterior

1

2

3

4

5

6

7

8

9

Siguiente